ReviewMolecular & cellular oncology
Role of the stem cell niche in the pathogenesis of epithelial ovarian cancers.
Review in Molecular & cellular oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Keratin 5 marks cancer-propagating cells sustained by an osteopontin-producing niche in high-grade serous ovarian carcinoma.bioRxiv : the preprint server for biology · 2026Article
- Keratin 5 marks cancer-propagating cells sustained by an osteopontin-producing niche in high-grade serous ovarian carcinoma.Cancer heterogeneity and plasticity · 2026Article
- Pre-ciliated tubal epithelial cells are prone to initiation of high-grade serous ovarian carcinoma.Nature communications · 2024Article
- Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populations.Scientific reports · 2023Article
- Gastric squamous-columnar junction contains a large pool of cancer-prone immature osteopontin responsive Lgr5Nature communications · 2020Article
- Chronic iron exposure and c-Myc/H-ras-mediated transformation in fallopian tube cells alter the expression of EVI1, amplified at 3q26.2 in ovarian cancer.Oncogenesis · 2019Article
- Stem Cell Pathology.Annual review of pathology · 2018Review
- LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells.Cell stem cell · 2017Article
- Transplantation Into the Mouse Ovarian Fat Pad.Journal of visualized experiments : JoVE · 2016Article
- Ovary and fimbrial stem cells: biology, niche and cancer origins.Nature reviews. Molecular cell biology · 2015Review
- A Quest for Better Mouse Models of Breast and Ovarian Cancers.EBioMedicine · 2015Article
- FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the United States. Recent extensive genomic analyses of epithelial ovarian cancer (EOC), particularly the most common and deadly form of high-grade serous ovarian carcinoma, have provided important insights into the repertoire of molecular aberrations that are characteristic for this malignancy. However, interpretation of the discovered aberrations is complicated because the origin and mechanisms of progression of EOC remain uncertain. Here, we summarize current views on the cell of origin of EOC and discuss recent findings of a cancer-prone stem cell niche for ovarian surface epithelium, one of the major likely sources of EOC. We also outline future directions and challenges in studying the role of stem cell niches in EOC pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.